학술논문
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Document Type
Article
Author
Source
In: The Lancet Infectious Diseases . (The Lancet Infectious Diseases, October 2019, 19(10):1091-1100)
Subject
Language
English
ISSN
14744457
14733099
14733099